

Special Issue

Diagnosis and Innovative Treatment of Localized Lung Cancer

Message from the Guest Editors

Lung cancer is still the leading cause of cancer-related death in Western countries. Screening programs using low-dose CT scanning in at-risk populations for smoking exposure have been demonstrated to be effective in reducing disease burden. Novel developments regarding molecular and circulating cellular markers for early diagnosis and prediction of treatment response are under development. New technologies, including neural network algorithms for imaging, high-throughput technologies for sequencing and multiple-fluorescence-activated cellular sorters, will change the diagnostic and prognostic paradigm for liquid biopsy and tumor tissue. Similarly, the treatment of early-stage disease is evolving, with emerging developments in integrated multidisciplinary management including immune system checkpoint inhibitors, lung-sparing surgery, molecularly target drugs and advanced radiotherapy. This Special Issue will present a series of papers focusing on novelties in the prevention, early diagnosis and treatment of localized lung cancer. Prof. Dr. Giulia Veronesi

Guest Editors

Prof. Dr. Giulia Veronesi

Dr. Piergiorgio Muriana

Dr. Pierluigi Novellis

Deadline for manuscript submissions

closed (10 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149651

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)